Publication

Overview of telehealth in the United States since the COVID-19 public health emergency: a narrative review

Downloadable Content

Persistent URL
Last modified
  • 06/25/2025
Type of Material
Authors
    Juan J Andino, University of California, Los AngelesNicholas W Eyrich, Emory UniversityRichard J Boxer, University of California, Los Angeles
Language
  • English
Date
  • 2023-07-15
Publisher
  • JMIR Publications
Publication Version
Copyright Statement
  • 2023 mHealth. All rights reserved.
License
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 9
Grant/Funding Information
  • Funding: None.
Supplemental Material (URL)
Abstract
  • Background and Objective The coronavirus disease 2019 (COVID-19) public health emergency (PHE) resulted in rapid expansion and use of telehealth services. Regulatory and reimbursement flexibilities were put in place to ensure patients had continued access to care while the health system was overwhelmed by COVID-19 cases. These changes have allowed clinicians to use and researchers to evaluate telehealth in new ways. Methods This narrative review focuses on highlighting telehealth research and evaluation that took place from March 2020 to February 2023 in the outpatient setting of the United States healthcare system. Key Content and Findings The research conducted during the COVID-19 PHE shows that telehealth was primarily used as a substitute for in-person care, to maintain continuity of care for established patients, and has not had a negative impact on clinical outcomes or resulted in increasing healthcare costs. Conclusions Studies show high patient and physician satisfaction, similar clinical outcomes and suggest that telehealth is used as a substitute for in-person care. The findings of this narrative review have direct implications for key stakeholders using telehealth now and beyond the COVID-19 pandemic. Patients, physicians and providers, healthcare leaders and administrators, as well as policymakers should consider how telehealth should continue to be reimbursed and regulated even as the COVID-19 PHE expired in May 2023.
Author Notes
  • Juan J. Andino, MD, MBA. Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA; UCLA Urology-The Men’s Clinic, 1260 15th St., Suite 1200, Santa Monica, CA 90404, USA. Email: juanjose@umich.edu
Keywords
Research Categories
  • Biology, Neuroscience
  • Health Sciences, Medicine and Surgery
  • Health Sciences, Oncology

Tools

Relations

In Collection:

Items